CRYOPORT, INC. Current Income Tax Expense (Benefit)
CRYOPORT, INC. (CYRX) reported Current Income Tax Expense (Benefit) of $1.55 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2026-03-05
- CRYOPORT, INC. current income tax expense (benefit) for the quarter ending 2013-03-31 was $0.00.
- CRYOPORT, INC. current income tax expense (benefit) for the quarter ending 2012-12-31 was $0.00.
- CRYOPORT, INC. current income tax expense (benefit) for the quarter ending 2012-09-30 was $2.00.
- CRYOPORT, INC. current income tax expense (benefit) for the quarter ending 2012-06-30 was $0.00, a 100.00% decline year-over-year.
- CRYOPORT, INC. current income tax expense (benefit) for fiscal 2025 was $1.55M, a 45.72% increase from fiscal 2024.
- CRYOPORT, INC. current income tax expense (benefit) for fiscal 2024 was $1.06M, a 43.28% decline from fiscal 2023.
- CRYOPORT, INC. current income tax expense (benefit) for fiscal 2023 was $1.87M, a 30.70% decline from fiscal 2022.
- CRYOPORT, INC. current income tax expense (benefit) for fiscal 2022 was $2.70M, a 42.69% increase from fiscal 2021.
| Period end | Current Income Tax Expense (Benefit) 3 month | Current Income Tax Expense (Benefit) 6 month | Current Income Tax Expense (Benefit) 9 month | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.55M 10-K · filed 2026-03-05 | ||||
| 2024-12-31 | $1.06M 10-K · filed 2026-03-05 | $1.72M 10-K · filed 2025-03-07 | |||
| 2023-12-31 | $1.87M 10-K · filed 2026-03-05 | $2.34M 10-K · filed 2024-03-13 | |||
| 2022-12-31 | $2.70M 10-K · filed 2025-03-07 | ||||
| 2021-12-31 | $1.90M 10-K · filed 2024-03-13 | ||||
| 2020-12-31 | $482.00K 10-K · filed 2023-02-28 | ||||
| 2019-12-31 | $41.00K 10-K · filed 2022-02-28 | ||||
| 2018-12-31 | $20.00K 10-K · filed 2020-03-10 | ||||
| 2017-12-31 | $5.00K 10-K · filed 2019-03-13 | ||||
| 2013-03-31 | $0.00 10-K · filed 2013-06-25 | $0.00 derived: sum of 2 quarters · filed 2013-06-25 | $2.00 derived: sum of 3 quarters · filed 2013-06-25 | $2.00 derived: sum of 4 quarters · filed 2013-06-25 | |
| 2012-12-31 | $0.00 10-K · filed 2013-06-25 | $2.00 derived: sum of 2 quarters · filed 2013-06-25 | $2.00 derived: sum of 3 quarters · filed 2013-06-25 | $2.00 derived: sum of 4 quarters · filed 2013-06-25 | |
| 2012-09-30 | $2.00 10-K · filed 2013-06-25 | $2.00 derived: sum of 2 quarters · filed 2013-06-25 | $2.00 derived: sum of 3 quarters · filed 2013-06-25 | $2.00 derived: sum of 4 quarters · filed 2013-06-25 | |
| 2012-06-30 | $0.00 10-K · filed 2013-06-25 | $0.00 derived: sum of 2 quarters · filed 2013-06-25 | $0.00 derived: sum of 3 quarters · filed 2013-06-25 | $0.00 derived: sum of 4 quarters · filed 2013-06-25 | |
| 2012-03-31 | $0.00 10-K · filed 2013-06-25 | $0.00 derived: sum of 2 quarters · filed 2013-06-25 | $0.00 derived: sum of 3 quarters · filed 2013-06-25 | $2.00 derived: sum of 4 quarters · filed 2013-06-25 | |
| 2011-12-31 | $0.00 10-K · filed 2013-06-25 | $0.00 derived: sum of 2 quarters · filed 2013-06-25 | $2.00 derived: sum of 3 quarters · filed 2013-06-25 | ||
| 2011-09-30 | $0.00 10-K · filed 2013-06-25 | $2.00 derived: sum of 2 quarters · filed 2013-06-25 | |||
| 2011-06-30 | $2.00 10-K · filed 2013-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |